BRAF and neoplasm: Dutch CRC guidelines recommend, in line with the European guidelines, to determine both mismatch repair status in stage II-IV tumors, and RAS and BRAF mutation status in tumor of patients with metastatic CRC prior to the start of systemic treatment28–30.